Development of live attenuated influenza vaccines against pandemic influenza strains

References

• Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360(25):2605-15
   PubMed Web of Science ®Google Scholar
• Friede M, Palkonyay L, Alfonso C, et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011;29(Suppl 1):A2-7
   PubMed Web of Science ®Google Scholar
• Karron RA, Callahan K, Luke C, et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009;199(5):711-16
   PubMed Web of Science ®Google Scholar
• Talaat KR, Karron RA, Callahan KA, et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009;27(28):3744-53
   PubMed Web of Science ®Google Scholar
• Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009;27(36):4953-60
   PubMed Web of Science ®Google Scholar
• Talaat KR, Karron RA, Luke CJ, et al. An open label phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011;29(17):3144-8
   PubMed Web of Science ®Google Scholar
• Talaat KR, Karron RA, Liang PH, et al. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses 2013;7(1):66-73
   PubMed Web of Science ®Google Scholar
• Quadrivalent influenza vaccine live, intranasal full prescribing information. MedImmune; Gaithersburg, MD, USA: 2013
   Google Scholar
• Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respir Viruses 2011;5(6):389-97
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir Viruses 2008;2(6):183-92
   Web of Science ®Google Scholar
• Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age. Vaccine 2012;30(20):3053-60
   PubMed Web of Science ®Google Scholar
• Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine 2012;30(19):2989-98
   PubMed Web of Science ®Google Scholar
• Toback SL, Ambrose CS, Eaton A, et al. A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. Vaccine 2013;31(14):1812-18
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012;30(5):886-92
   PubMed Web of Science ®Google Scholar
• Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282(2):137-44
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Wu X, Jones T, Mallory RM. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 2012;30(48):6794-801
   PubMed Web of Science ®Google Scholar
• Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008;15(7):1042-53
   PubMed Web of Science ®Google Scholar
• Coelingh K, Wu X, Mallory R, Ambrose CS. Serum HAI antibody response to LAIV in 2- to 49-year-olds. Pediatric Academic Societies Annual Meeting; 4–7 June 2013;Washington, DC, USA
   Google Scholar
• Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011;10(8):1131-41
   PubMed Web of Science ®Google Scholar
• He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006;80(23):11756-66
   PubMed Web of Science ®Google Scholar
• Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011;204(6):845-53
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011;162(1-2):19-30
   PubMed Web of Science ®Google Scholar
• Block SL, Toback SL, Yi T, Ambrose CS. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a subgroup analysis of children 2 to 6 years of age. Clin Ther 2009;31(10):2140-7
   PubMed Web of Science ®Google Scholar
• Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007;120(3):e553-64
   Web of Science ®Google Scholar
• Jin H, Lu B, Zhou H, et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003;306(1):18-24
   PubMed Web of Science ®Google Scholar
• Suguitan AL Jr, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006;3(9):e360
   PubMed Web of Science ®Google Scholar
• Min JY, Vogel L, Matsuoka Y, et al. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J Virol 2010;84(22):11950-60
   PubMed Web of Science ®Google Scholar
• Jin H, Chen Z, Liu J, Kemble G. Genetic engineering of live attenuated influenza viruses. Methods Mol Biol 2012;865:163-74
   PubMedGoogle Scholar
• Chen Z, Wang W, Zhou H, et al. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010;84(1):44-51
   PubMed Web of Science ®Google Scholar
• Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004;363(9409):617-19
   PubMed Web of Science ®Google Scholar
• Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004;430(6996):209-13
   PubMed Web of Science ®Google Scholar
• Guan Y, Poon LL, Cheung CY, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci USA 2004;101(21):8156-61
   PubMed Web of Science ®Google Scholar
• Chen H, Matsuoka Y, Swayne D, et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003;21(27-30):4430-6
   PubMed Web of Science ®Google Scholar
• Joseph T, McAuliffe J, Lu B, et al. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J Virol 2007;81(19):10558-66
   PubMed Web of Science ®Google Scholar
• Gillim-Ross L, Santos C, Chen Z, et al. Avian influenza H6 viruses productively infect and cause illness in mice and ferrets. J Virol 2008;82(21):10854-63
   PubMed Web of Science ®Google Scholar
• Jin H, Manetz S, Leininger J, et al. Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine 2007;25(52):8664-72
   PubMed Web of Science ®Google Scholar
• Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993;168(4):881-7
   PubMed Web of Science ®Google Scholar
• Murphy BR, Tierney EL, Barbour BA, et al. Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines. Infect Immun 1980;29(2):342-7
   PubMed Web of Science ®Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37(4):937-43
   PubMed Web of Science ®Google Scholar
• Clements ML, O’Donnell S, Levine MM, et al. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983;40(3):1044-51
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19(13-14):1732-7
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21(15):1687-93
   PubMed Web of Science ®Google Scholar
• Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008;198(5):635-41
   PubMed Web of Science ®Google Scholar
• Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013;13(3):238-50
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011;11(12):916-24
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Zephir K, Hu Z, et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the h5 DNA influenza vaccine priming effect. J Infect Dis 2013;208(3):418-22
   PubMed Web of Science ®Google Scholar
• Talaat KR, Luke CJ, Khurana S, et al. A live attenuated H5N1 vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Mallory RM, Malkin E, Ambrose CS, et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 2010;5(10):e13755
   PubMed Web of Science ®Google Scholar
• Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011;6(8):e23085
   PubMed Web of Science ®Google Scholar
• Uzicanin A, Thompson M, Smith P, et al. Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in Maine. J Infect Dis 2012;206(7):1059-68
   PubMed Web of Science ®Google Scholar
• Chen Z, Santos C, Aspelund A, et al. Evaluation of live attenuated influenza A virus H6 vaccines in mice and ferrets. J Virol 2009;83(1):65-72
   PubMed Web of Science ®Google Scholar